ASPECTS OF TREATMENT OF ATRIAL FIBRILLATION IN PATIENTS WITH CONCOMITANT HEART DISEASE IN FAMILY DOCTOR PRACTICE
Keywords:
atrial fibrillation, the treatmentAbstract
The article provides a retrospective analysis of published data on combination therapy and rational strategy to control the rhythm in patients with atrial fibrillation with concurrent heart disease. The main goal of treatment is to improve the quality of life and the prevention of complications and death. Treatment should be aimed at the restoration and preservation of sinus rhythm, or when it is impossible — slowing ventricular rate and the prevention of thromboembolic complications.
References
Outpatient treatment of ESC Guidelines 2425 recent-onset atrial fibrillation with the ‘pill-in-the-pocket’ approach / P. Alboni, G. L. Botto, N. Baldi [et al.] // N Engl J Med. – 2004. – Vol. 351. – P. 2384–2391.
Synergistic Effect of the Combination of Ranolazine and Dronedarone to Suppress Atrial Fibrillation / A. Burashnikov, S. Sicouri, José M. Di Diego [et al.] // J Am Coll Cardiol. – 2010, Oct 5. – Vol. 56 (15). – P. 1216–1224.
Alonso A. A rising tide: The global epidemic of atrial fibrillation / A. Alonso, L. G. Bengtson // Circulation. – 2014. – Vol. 129. – P. 829–830.
Aslam S. Ranolazine (Renexa) in the treatment of chronic stable angina. Advances in Therapy / S. Aslam, D. Gray. – 2010. – Vol. 27 (4). – P. 193–201.
Bassand J.-P. Clinical implications of inhibitor of the late sodium current: ranolazine / J.-P. Bassand // Eur Heart J. – 2006. – Vol. 8 (Suppl. A). – P. A14–A19.
Guidelines for themanagement of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) / A. J. Camm, P. Kirchhof, G. Y. Lip [et al.] // Eur Heart J. – 2010. – Vol. 31. – P. 2369–2429.
A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent onset atrial fibrillation / A. J. Camm, A. Capucci, S. Hohnloser [et al.] // J Am Coll Cardiol. – 2011. – Vol. 57 (3). – P. 313–321.
Worldwide epidemiology of atrial fibrillation: A global burden of disease 2010 Study / S. S. Chugh, R. Havmoeller, K. Narayanan [et al.] // Circulation. – 2014. – Vol. 129 (8). – P. 837–847.
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial / S. Connolly, J. Pogue, R. Hart [et al.] // Lancet. – 2006. – Vol. 367. – P. 1903–1912.
Effect of clopidogrel added to aspirin in patients with atrial fibrillation / S. J. Connolly, J. Pogue, R. G. Hart [et al.] / / N Engl J Med. – 2009. – Vol. 360. – P. 2066–2078.
Dabigatran versus warfarin in patients with atrial fibrillation / S. J. Connolly, M. D. Ezekowitz, S. Yusuf [et al.] // N Engl J Med. – 2009. – Vol. 361. – P. 1139–1151.
Hart R. G. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation / R. G. Hart, L. A. Pearce, M. I. Aguilar // Ann Intern Med. – 2007. – Vol. 146. – P. 857–867.
Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, doubleblind, placebo-controlled trial / P. R. Kowey, P. Dorian, L. B. Mitchell [et al.] // Circ Arrhythm Electrophysiol. – 2009. – Vol. 2. – P. 652–659.
A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of Euro Observational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry / G. Y. Lip, C. Laroche, G. A. Dan [et al.] // Europace. – 2014. – Vol. 16 (3). – P. 308–316.
Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group ‘Hypertension Arrhythmias and Thrombosis’ of the European Society of Hypertension / A. J. Manolis, E. A. Rosei, A. Coca [et al.] // J Hypertens. – 2012. – Vol. 30. – P. 239–252.
Michels G. Ranolazine — an additional anti-anginal drug / G. Michels, M. Kochanek, U. C. Hoppe // Dtsch Med Wochenschr. – 2010. – Vol. 135 (41). – P. 2037–2040.
Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study / S. Ogawa, T. Yamashita, T. Yamazaki [et al.] // Circ J. – 2009. – Vol. 73. – P. 242–248.
Patel P. D. Utility of ranolazine in chronic stable angina patients / P. D. Patel, R. R. Arora // Cardiovasc Health Risk Manag. – 2008. – Vol. 4 (4). – P. 819–824.
Reddy B. M. Ranolazine. A New Approach to Treating an Old Problem / B. M. Reddy, H. S. Weintraub, A. Z. Schwartzbard // Tex Heart Inst J. – 2010. – Vol. 37 (6). – P. 641–647.
Comparison of antiarrhythmic drug therapy and radio frequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial / D. J. Wilber, C. Pappone, P. Neuzil [et al.] // JAMA. – 2010. – Vol. 303. – P. 333–340.
